Browsing Tag
biopharma
13 posts
Is Eli Lilly (LLY) building the obesity drug supply chain nobody else can easily match?
Lilly’s obesity pipeline needs industrial muscle. Its $4.5bn Indiana bet shows why manufacturing may decide the next GLP-1 race.
Why is Trinity’s Digital Twins launch more than just another generative AI product announcement for life sciences?
Trinity has launched Digital Twins for life sciences teams. Find out why this AI move could reshape pharma commercial strategy and market research.
Verana Health and Guardant Health link genomics and real-world data to accelerate precision oncology drug
Verana Health and Guardant Health (GH) combine EHR and genomic data to accelerate oncology drug development. Read the full strategic analysis.
Mazdutide phase 1b results from Innovent Biologics offer new hope for adolescent obesity in China
Find out how Innovent Biologics’ mazdutide trial could change adolescent obesity treatment in China—phase 3 launch is next.
Can 7.2 mg Wegovy redefine the weight loss standard in obesity treatment?
Novo Nordisk files for FDA approval of 7.2 mg Wegovy with fast-track priority review. See what this higher dose means for the future of obesity treatment.
Novo Nordisk’s Alzheimer’s treatment hopes crash as semaglutide fails to slow cognitive decline
Novo Nordisk’s GLP-1 pill failed in Alzheimer’s trials, raising questions on neurology diversification. Read what this means for its pipeline and stock.
Biotech breakthrough in PTSD? Silo Pharma and Allucent move toward FDA IND filing for SPC-15 therapy
Silo Pharma partners with Allucent to advance its planned FDA IND for intranasal PTSD therapeutic SPC-15. Find out how this collaboration could shape future mental health treatment.
PharmaResearch spin-off approved: Strategic realignment to create holding and operating firms by November 2025
PharmaResearch to restructure into holding and operating entities by Nov 2025, aiming to sharpen focus and boost global competitiveness. Read full analysis.
Q32 Bio’s bempikibart shows signs of a remittive effect in alopecia areata—Here’s what that means
Q32 Bio Inc. has released promising SIGNAL-AA trial results, shedding new light on the potential of bempikibart clinical…
Biocon launches generic Tacrolimus in U.S.: A gamechanger in transplant care
Find out how Biocon’s launch of generic Tacrolimus in the U.S. marks a strategic leap in affordable transplant care and global generic market expansion.